https://www.selleckchem.com/pr....oducts/idasanutlin-r
Seven studies were selected, all performed in the US or Canada. Five studies were funded by IIV3-HD manufacturer, and the remaining two by the US National Institute of General Medical Sciences. In all studies, IIV3-HD reduces healthcare resource utilization and is cost-effective or cost-saving compared to IIV3-SD. The main driver is reduced hospitalizations for cardiorespiratory events. IIV3-HD is cost-saving or cost-effective versus IIV3-SD in adults aged ≥65years. Reduced cardiorespiratory complications are an important dr
Curtir
Comentario
Compartilhar
